ZNF385B and breast cancer: In addition, low ZNF385B expression significantly affected the RFS in infiltrating ductal carcinoma (p < 0.0001), ER-negative BC (p = 0.016), ER-positive BC (p = 0.025), PR-negative BC (p = 0.00044), HER-2-negative BC (p = 0.00069), HER-2-positive BC (p = 0.048), and basal-like BC (p = 0.039) through subgroup analysis.